Mechanism Overview: Targeting the Enzyme That Produces DHT
Finasteride is a synthetic 4-azasteroid compound that specifically inhibits type II 5-alpha-reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in target tissues. DHT is approximately 5 times more potent than testosterone as an androgen receptor agonist, and it is the primary hormonal driver of androgenetic alopecia (AGA). By reducing DHT production, finasteride addresses the root cause of follicular miniaturization in AGA—a fundamentally different approach from minoxidil, which works downstream of androgen signaling.
The development of finasteride for hair loss followed from its initial FDA approval for benign prostatic hyperplasia (BPH) at a 5mg dose (Proscar). Researchers observed that BPH patients taking finasteride experienced increased hair growth, leading to clinical trials at the lower 1mg dose specifically for AGA. Finasteride 1mg (Propecia) received FDA approval for male pattern hair loss in 1997, making it the first oral medication approved for this indication.
Detailed Mechanism: Type II 5-Alpha-Reductase Inhibition
5-Alpha-reductase exists as two distinct isoenzymes: type I and type II. Type I is predominantly expressed in the liver, skin (particularly sebaceous glands), and brain, while type II is the predominant form in the prostate, epididymis, seminal vesicles, and—critically—the hair follicle inner root sheath and dermal papilla. Finasteride selectively inhibits type II with an IC50 of approximately 10 nM, while having minimal effect on type I (IC50 > 10,000 nM).
Finasteride works as a competitive, mechanism-based inhibitor. It binds to the enzyme’s active site and, through a slow, tightly binding interaction, effectively inactivates the enzyme. The inhibition is essentially irreversible on the timescale of drug metabolism, meaning that new enzyme must be synthesized to restore 5-alpha-reductase activity. This is why finasteride has a prolonged biological effect that exceeds its plasma half-life of approximately 6-8 hours—once the enzyme is inhibited, recovery requires de novo protein synthesis.
The consequence of type II inhibition is a significant reduction in DHT levels. In clinical studies, 1mg finasteride daily reduces scalp DHT by approximately 64% and serum DHT by approximately 70%. Testosterone levels typically increase modestly (by approximately 10-15%) due to reduced conversion to DHT, but this increase is usually clinically insignificant.
The reduction in scalp DHT has direct effects on hair follicle biology. DHT binds to androgen receptors (AR) in the dermal papilla cells of susceptible follicles, activating a transcriptional program that includes upregulation of TGF-β1, TGF-β2, and DKK-1—all of which are catagen-promoting and growth-inhibitory factors. By reducing DHT, finasteride attenuates this signaling cascade, allowing follicles to maintain their anagen phase and resist miniaturization.
Downstream Effects on Follicle Biology
The downstream effects of DHT reduction extend beyond simply removing the brake on hair growth. Research by Kwack et al. (2008), published in the Journal of Dermatological Science, demonstrated that DHT upregulates DKK-1 (dickkopf-1) expression in dermal papilla cells from balding scalp but not from non-balding scalp. DKK-1 is a potent inhibitor of the Wnt/β-catenin pathway, which is needed for hair follicle morphogenesis and anagen maintenance. This finding provides a direct molecular link between androgen signaling and the Wnt pathway.
Furthermore, DHT has been shown to upregulate TGF-β2 expression in dermal papilla cells (Inui et al. 2003, Journal of Investigative Dermatology). TGF-β2 is one of the most potent catagen-promoting factors identified, and its upregulation by DHT provides a mechanism by which androgens promote the transition from anagen to catagen in susceptible follicles.
Research Evidence: Clinical Trials and Meta-Analyses
The clinical evidence for finasteride is among the most strong for any hair loss treatment. The important trial by Kaufman et al. (1998), published in the Journal of the American Academy of Dermatology, enrolled 1,553 men with AGA (Hamilton-Norwood grades II-V) and randomized them to finasteride 1mg or placebo for 12 months. Results showed that 86% of the finasteride group maintained or increased hair count versus 42% of the placebo group. The mean hair count increase in the finasteride group was 11% at 12 months.
Long-term data demonstrate sustained efficacy over 5 years, with treated patients showing a net improvement of approximately 10% in hair count compared to baseline, while the placebo group continued to decline. A meta-analysis by Mella et al. (2010), published in the Archives of Dermatology, analyzed 12 randomized controlled trials and confirmed that finasteride 1mg daily significantly increases hair count and improves both patient and investigator assessments of hair growth.
In women, the evidence is largely negative. A large RCT by Price et al. (2000), published in the Journal of the American Academy of Dermatology, found that finasteride 1mg daily was no more effective than placebo in postmenopausal women with female pattern hair loss over 12 months. This may reflect the different hormonal milieu in female hair loss, where factors other than DHT play a more prominent role.
Limitations and Safety Concerns
Finasteride has several important limitations. It only inhibits type II 5-alpha-reductase, leaving type I activity (which contributes approximately 30% of scalp DHT) unaffected. Dutasteride, which inhibits both isoenzymes, produces more complete DHT suppression (approximately 90% vs. 70%) but is not FDA-approved for hair loss and carries a higher risk of side effects.
Finasteride is primarily effective for vertex and mid-scalp hair loss; its efficacy for frontal/temporal recession is more modest. Sexual side effects occur in approximately 1-2% of patients in clinical trials, including decreased libido, erectile dysfunction, and ejaculatory disorders. The FDA added a warning about “post-finasteride syndrome” to the label in 2012, though its existence as a distinct clinical entity remains debated. A systematic review by Zhou et al. (2019) in the Journal of Sexual Medicine found no conclusive evidence that persistent adverse effects are caused by finasteride.
Finasteride reduces PSA levels by approximately 50%, which can mask the detection of prostate cancer. It is absolutely contraindicated in women of childbearing potential due to teratogenic risk.
Frequently Asked Questions
Does finasteride regrow hair or just prevent loss? Clinical trials show both prevention of further loss and modest regrowth (approximately 10% increase in hair count at 12 months). Its primary effect is maintenance.
Can I combine finasteride with minoxidil? Yes. The combination is common and logical, as the drugs work through entirely different mechanisms. Studies demonstrate that the combination produces superior results to either agent alone.
What happens if I stop? Hair loss resumes within 6-12 months, and you will likely return to the trajectory you would have been on without treatment.
Conclusion
Finasteride remains the most effective oral treatment for androgenetic alopecia in men, with a well-characterized mechanism involving selective type II 5-alpha-reductase inhibition and downstream reduction in DHT-mediated catagen promotion. Its clinical efficacy is supported by multiple large RCTs and 5-year follow-up data. However, its limitations—including incomplete DHT suppression, modest frontal efficacy, sexual side effects in a minority of patients, and the need for lifelong use—must be clearly communicated. The ongoing debate about post-finasteride syndrome warrants honest discussion with patients considering this treatment.